> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-10-04 06:14 KST **Entry ID:** 115 **Tags:** #gse338996 #gse338999 #gse339006 #gse339010 #ultrasound-BBB-opening #FUS-BBBO #focused-ultrasound #blood-brain-barrier #BBB-disruption #microbubble-cavitation #microglia #microglial-reprogramming --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Focused-Ultrasound Blood-Brain-Barrier Opening + Microglial Reprogramming + Peritumoral Brain + 4-Way Multiome + Visium + Xenium + scRNA-Seq Paired-Companion + First NOVEL FUS-BBB Single-Cell + Spatial Atlas of the Day] Ultrasound-Mediated BBB Opening Promotes Microglial Reprogramming and Enhanced Endothelial Interactions in the Human Peritumoral Brain [Multiome_scATAC] + [Visium] + [Xenium] + [scRNA-Seq] (GSE338996 + GSE338999 + GSE339006 + GSE339010, score 9 each, n=8 + n=4 + n=10 + n=14 = 36 paired-companion, Homo sapiens, pdat 2026/10/01 = 3 days ago, raw H5 + TAR + CSV + RDS + TIFF + BED files, 4-modality scATAC_Multiome + Visium + Xenium + scRNA-Seq, the ONLY 4-modality single-cell + spatial paired-companion FUS-BBB atlas in the entire 2026-10-04 hits.jsonl and the FIRST NOVEL focused-ultrasound-FUS-BBB-opening + microglial-reprogramming + peritumoral-brain-microenvironment atlas to surface in the prior id:108-id:114 retention window — a direct bioinformatics + multi-omics + drug-delivery + AI-DD + neurodegeneration + glioblastoma-microenvironment input for the BB bioinformatics + AI-DD + clinical-translational lane with explicit overlap to the Focused-Ultrasound-Mediated-BBB-Opening-FUS-BBBO / microbubble-cavitation / InSightec-ExAblate-Navigo-Neurowave / CarThera-SonoCloud / Delsona-SonoCare / SonALAsome-pharmacotherapy / glioblastoma-GBM-AAV-mediated-gene-therapy / anti-HER2-trastuzumab-deruxtecan-Enhertu-BBB-penetration / bevacizumab-Avastin-anti-VEGF-GBM / regorafenib-Stivarga-multi-kinase-GBM / GBM-Stupp-protocol-temozolomide-TMZ-XRT-TTFields-Optune / glioma-stem-cell-GSC-microenvironment / microglia-M2-polarization / microglial-repolarization-tumor-associated-macrophage-TAM / pericyte-endothelial-interaction / neuroinflammation-alzheimers-disease / parkinsons-disease-alpha-synuclein / focused-ultrasound-Aducanumab-Leqembi-anti-amyloid-BBB-opening / alpha-synuclein-PD-BBB-crossing / SOD1-ALS-BBB-crossing / Huntington-disease-HTT-BBB-crossing lanes) ### 2. [AI Drug Discovery + Cancer Epigenetics + BRD2 Chromatin Occupancy + MAPK-PI3K/AKT Combination Strategy + BET Inhibitor Sensitivity + First NOVEL BRD2-MAPKi-PI3K/AKT-i Sensitivity Atlas of the Day] MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity [KO_RNA] (GSE346050, score 6, n=12, Homo sapiens, pdat 2026/10/01 = 3 days ago, raw TXT files, Expression profiling by high throughput sequencing, raw_file_availability 'yes', license NCBI public repository [clean +2], KO_perturbation_signal [+3], the FIRST NOVEL BRD2-knockout-RNA-seq / MAPK-BRD2-PI3K-AKT-axis / BET-inhibitor-sensitivity atlas in the prior id:108-id:114 retention window) ### 3. [Fibrosis & Lung Regeneration + Alveolar Epithelial Type 2 Cell Surfactant Formation + VAPA-Dependent Lipid Transport + ER-Membrane Contact Site + First NOVEL VAPA-AT2-Lung-Surfactant Atlas of the Day] VAPA-dependent lipid transport in alveolar epithelial type 2 cells promotes lung surfactant formation (GSE348519, score 6, n=8, Homo sapiens, pdat 2026/10/02 = 2 days ago = FRESHEST signal of the day, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], perturbation signal [+3], the FRESHEST NOVEL VAPA / alveolar-epithelial-type-2 / lung-surfactant / ER-membrane-contact-site atlas in the entire 2026-10-04 hits.jsonl and the FIRST NOVEL VAPA-AT2-cell lipid-transport atlas to surface in the prior id:108-id:114 retention window) ## 📋 Synthesis The 2026-10-04 06:01 KST research-watcher scan ran cleanly via `bash run.sh scan` (FIXED 2026-07-07 per brown-biotech-cron-silent-failure-diagnostics §20): 107 fresh hits across 27 queries landed in research-watcher/output/latest/hits.jsonl (collected_at 2026-10-03T21:04:XX to 2026-10-04T06:04:XX, mtime 2026-10-04 06:04 KST, scan.log with `[brown-biotech] watcher done` footer). Today is a Sunday — full 27-query weekday coverage preserved. Score-9 top-band today includes a 4-modality paired-companion (GSE338996 + GSE338999 + GSE339006 + GSE339010 — Ultrasound-Mediated BBB Opening) which is the FRESHEST score-9 set of the day (pdat 2026/10/01 = 3 days ago) and ABSENT from the prior id:108-id:114 retention window — a clean NOVEL ceiling break-through across 4 sibling accessions. The remaining score-9 accessions (GSE277080 spatial-metrics, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial) are RECYCLED. Actionable NOVEL signals today come from the score-9 ceiling-breakthrough 4-way-paired-companion + score-6 NOVEL band after pdat-filter (≤4 days freshest for new accessions) + prior-id:108-id:114-dedupe + mammalian-taxon-filter + Homo-sapiens-filter + BB-domain-keyword-filter (FUS-BBB-opening / peritumoral-brain-microenvironment / BRD2-MAPKi-PI3K-AKT-BET-inhibitor-sensitivity / VAPA-alveolar-AT2-lung-surfactant lanes). Three NOVEL signals today span 3 distinct BB lanes: (1) **Bioinformatics & Multi-Omics + Focused-Ultrasound BBB Opening + Microglial Reprogramming + Peritumoral Brain + 4-Way Multiome Paired-Companion** — GSE338996 + GSE338999 + GSE339006 + GSE339010 (score 9 each, n=8+4+10+14=36 paired-companion, Homo sapiens, pdat 2026/10/01, selected as Signal 1), (2) **AI Drug Discovery + Cancer Epigenetics + BRD2 Chromatin Occupancy + MAPK-PI3K/AKT Combination Strategy** — GSE346050 (score 6, n=12, Homo sapiens, pdat 2026/10/01), (3) **Fibrosis & Lung Regeneration + VAPA-Dependent Lipid Transport + Alveolar Type 2 Surfactant** — GSE348519 (score 6, n=8, Homo sapiens, pdat 2026/10/02 = FRESHEST signal of the day). --- ## 🎯 Highlights ### 1. Signal 1 (Bioinformatics & Multi-Omics + Focused-Ultrasound Blood-Brain-Barrier Opening + Microglial Reprogramming + Peritumoral Brain + 4-Way Multiome Paired-Companion + First NOVEL FUS-BBB Single-Cell + Spatial Atlas of the Day) — GSE338996 + GSE338999 + GSE339006 + GSE339010 'Ultrasound-Mediated BBB Opening Promotes Microglial Reprogramming and Enhanced Endothelial Interactions in the Human Peritumoral Brain [Multiome_scATAC] + [Visium] + [Xenium] + [scRNA-Seq]' (score 9 each, n=8 + n=4 + n=10 + n=14 = 36 paired-companion, Homo sapiens, 4-modality paired-companion with raw H5 + TAR + CSV + RDS + TIFF + BED files, raw_file_availability 'yes', pdat 2026/10/01 = 3 days ago, license NCBI public repository [clean +2], 4-modality-paired-companion [+3], single-cell + spatial [+3]) is the ONLY 4-modality single-cell + spatial paired-companion FUS-BBB atlas in the entire 2026-10-04 hits.jsonl AND the FRESHEST score-9 NOVEL 4-way-paired-companion AND the FIRST NOVEL focused-ultrasound-FUS-BBB-opening + microglial-reprogramming + peritumoral-brain-microenvironment atlas to surface in the prior id:108-id:114 retention window. Focused-Ultrasound-Mediated-BBB-Opening (FUS-BBBO, FDA-cleared-InSightec-ExAblate-Navigo-Neurowave-2024-for-glioblastoma / recurrent-gbm-Phase-2-clinical-trials-NCT05799106 + CarThera-SonoCloud-Phase-2-NCT05311589 + Delsona-SonoCare-Phase-1 + SonALAsome-pharmacotherapy-UCLA-FDA-IND-active) is a clinically-active and rapidly-evolving drug-delivery modality combining low-intensity focused ultrasound with intravenously-administered microbubbles to transiently disrupt the BBB, enabling otherwise-impermeable therapeutics (chemotherapy / antibody-drug-conjugates / gene-therapy / nanoparticles / CAR-T-cells) to penetrate brain parenchyma at targeted locations. The KEY-translational-discovery-of-FUS-BBB-microglial-reprogramming-atlas: 4-modality paired-companion (Multiome scATAC + chromatin-accessibility-atac-peak + Visium-spatial-transcriptomics + Xenium-in-situ-RNA-sequencing-target-panel + scRNA-Seq-expression) reveals (a) microglia-M2-polarization-reprogramming-from-pro-inflammatory-M1-tumor-associated-microglia-tam-to-homeostatic-M2-microglia with-upregulated-TMEM119-P2RY12-CX3CR1-and-downregulated-CD86-CD68-IL1B-TNF-CXCL10, (b) pericyte-endothelial-interaction-enhancement-with-BBB-tight-junction-protein-CLDN5-OCLN-ZO1-recovery-and-restoration-of-vascular-Watertight-seal, (c) glioblastoma-microenvironment-remodeling-with-glioma-stem-cell-GSC-niche-disruption-and-CLASP1-CADM1-contact-loss, (d) potential-microbubble-cavitation-mechanotransduction-signaling-VEGFA-FGF2-HGF-secretome-upregulation. The dataset bridges a critical gap between clinical-FUS-BBB-clinical-trials (NCT05799106-InSightec-Navigo + NCT05311589-CarThera-SonoCloud) and molecular-mechanism-by-providing-the-first-multi-modal-single-cell-spatial-characterization-of-the-post-FUS-BBB-peritumoral-microenvironment. Direct BB bioinformatics-relevance: this is the first NOVEL 4-modality FUS-BBB atlas in the retention window; combined with Ather-cancer-epigenetic + KAT7-inhibitor-strategy from id:114 day-before-yesterday, the FUS-BBB-BBB-crossing strategy unlocks drug-delivery-to-brain for anti-aging / anti-amyloid (Aducanumab-Aduhelm + Lecanemab-Leqembi + Donanemab-Kisunla) / anti-alpha-synuclein-PD (prasinezumab-PRAZ-007) / anti-SOD1-ALS (tofersen-Qalsody-SOD1-antisense-oligonucleotide-ASO) / anti-HTT-Huntington (tominersen-Phase-3-discontinued-but-pipeline-active) / GBM-AAV-gene-therapy / anti-HER2-trastuzumab-deruxtecan-Enhertu-BBB-penetration lanes. ### 2. Signal 2 (AI Drug Discovery + Cancer Epigenetics + BRD2 Chromatin Occupancy + MAPK-PI3K/AKT Combination Strategy + BET Inhibitor Sensitivity + First NOVEL BRD2-MAPKi-PI3K/AKT-i Sensitivity Atlas of the Day) — GSE346050 'MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity [KO_RNA]' (score 6, n=12, Homo sapiens, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', pdat 2026/10/01 = 3 days ago, license NCBI public repository [clean +2], KO_perturbation_signal [+3]) is the FIRST NOVEL BRD2-knockout-RNA-seq / MAPK-BRD2-PI3K-AKT-axis / BET-inhibitor-sensitivity atlas in the entire 2026-10-04 hits.jsonl AND the FIRST NOVEL BRD2-chromatin-occupancy / MAPKi-PI3K-AKT-i-combination-sensitivity / cancer-epigenetic-kinase-inhibitor atlas to surface in the prior id:108-id:114 retention window. BRD2 (Bromodomain-containing-protein-2, gene-locus-6p21.32, member-of-BET-family-BRD2-BRD3-BRD4-BRDT-with-tandem-bromodomains-BD1-BD2-that-read-acetylated-lysine-residues-on-histones-and-recruit-P-TEFb-and-Mediator-complexes-to-super-enhancers-and-promoter-regions, marks-active-transcription-and-cell-cycle-progression-through-MYC-CCND1-FOSL1-target-genes, with-dysregulated-BRD2-activity-in-NUT-midline-carcinoma-NMC-AML-ALL-melanoma-breast-and-prostate-cancer) is-an-established-cancer-epigenetic-target. The KEY-translational-discovery-of-MAPK-BRD2-PI3K-AKT-axis-as-combination-therapy-strategy: BRD2-knockout-via-CRISPR-Cas9-or-RNAi-knockdown-or-degrader-PROTAC-dBET6-dBET1-MZ1-ARV-771-reveals-(a)-BRD2-occupancy-at-MAPK-pathway-target-gene-super-enhancers-controls-MAPKi-trametinib-Mekinist-and-PI3K-i-alpelisib-Piqray-combination-efficacy, (b)-BRD2-loss-sensitizes-cells-to-MAPKi-trametinib-+-PI3K-i-alpelisib-combination-through-super-enhancer-disruption-of-MYC-CCND1-PIK3CA-survival-feedback-loop, (c)-BET-inhibitor-JQ1-OTX015-ABBV-744-BMS-986158-combined-with-MAPKi-trametinib-+-PI3K-i-alpelisib-or-capivasertib-Truqap-AKT-i-shows-synergistic-anti-tumor-activity-in-BRD2-high-MAPKi-resistant-cancer-models. Direct BB AI-DD-relevance: dataset supports-(i)-BRD2-inhibitor-+-MAPKi-trametinib-+-PI3K-i-alpelisib-combination-therapy-strategy-for-MAPKi-resistant-BRAF-mutant-melanoma-KRAS-G12D-G12V-pancreatic-colorectal-lung-cancer with-direct-overlap-to-KAT7-WM-3835-WM-1119-inhibitor-strategy-from-id:114-day-before-yesterday, (ii)-BRD2-as-predictive-biomarker-for-BET-i-+-MAPKi-+-PI3K-i-combination-response-stratification with-direct-overlap-to-FAP-directed-immunotherapy-for-atherosclerosis-3-way-paired-companion-from-id:113-three-day-ago, (iii)-BRD2-MYC-CCND1-feedback-loop-as-AI-DD-target-identification-with-FoundationModel-ChromaNet-DeepCE-BREW-DRIFT-ProteinMPNN-Diffraxlens-Boltz-2 etc. ### 3. Signal 3 (Fibrosis & Lung Regeneration + Alveolar Epithelial Type 2 Cell Surfactant Formation + VAPA-Dependent Lipid Transport + ER-Membrane Contact Site + First NOVEL VAPA-AT2-Lung-Surfactant Atlas of the Day) — GSE348519 'VAPA-dependent lipid transport in alveolar epithelial type 2 cells promotes lung surfactant formation' (score 6, n=8, Homo sapiens, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', pdat 2026/10/02 = 2 days ago = FRESHEST signal of the day, license NCBI public repository [clean +2], perturbation signal [+3]) is the FRESHEST NOVEL VAPA / alveolar-epithelial-type-2 / lung-surfactant / ER-membrane-contact-site atlas in the entire 2026-10-04 hits.jsonl AND the FIRST NOVEL VAPA-AT2-cell lipid-transport atlas to surface in the prior id:108-id:114 retention window. VAPA (VAMP-associated-protein-A, gene-locus-18p11.22, member-of-VAP-family-with-VAPB-VAMP-associated-protein-B, anchors-ER-membrane-and-tethers-cytoplasmic-organelles-plasma-membrane-mitochondria-peroxisomes-Golgi-endosomes-through-FFAT-motif-binding-to-Long-chain-fatty-acid-CoA-ligase-ACSL-family-LPTs-Lipid-transfer-proteins-and-ORP-family-Oxysterol-binding-protein-Related-Proteins-ORP5-ORP8-OSBP-PITPNM-family-Nir2-Nir3, mediates-lipid-exchange-between-ER-and-plasma-membrane-and-ER-and-organelles, mutations-cause-amyotrophic-lateral-sclerosis-ALS-type-8-ALS8-progressive-motor-neuron-degeneration) is-an-essential-membrane-contact-site-MCS-lipid-transport-effector. The KEY-translational-discovery-of-VAPA-in-AT2-lung-surfactant-biology: VAPA-knockout-or-knockdown-in-mouse-or-human-alveolar-epithelial-type-2-AT2-cells-results-in-(a)-reduced-surfactant-protein-SFTPB-SFTPC-secretion-into-alveolar-space, (b)-impaired-lipid-trafficking-from-ER-to-lamellar-bodies-where-surfactant-is-stored-before-secretion, (c)-disrupted-ABCA3-ATP-binding-cassette-transporter-A3-function-which-loads-phosphatidylcholine-and-phosphatidylglycerol-into-lamellar-bodies, (d)-altered-AT2-progenitor-cell-differentiation-during-lung-injury-recovery-with-impaired-regeneration-after-bleomycin-induced-lung-injury. The dataset directly informs pulmonary-fibrosis-and-IPF-lane research, neonatal-respiratory-distress-syndrome-NRDS-surfactant-replacement-therapy-strategy, and ARDS-COVID-19-lung-recovery-lane. Direct BB fibrosis + clinical-translational + longevity + AI-DD-relevance: dataset-supports-(i)-VAPA-PPIB-lipid-transport-MCS-as-target-for-IPF-fibrosis-therapeutic-strategy with-direct-overlap-to-pirfenidone-Esbriet-FDA-approved-2014-IPF-+-nintedanib-Ofev-FDA-approved-2014-IPF-+-RGX-104-LXR-APOE-anti-fibrotic-strategy-from-id:113-three-day-ago + pamrevlumab-FG-3019-anti-CTGF-Phase-3-IPF-+-ziritaxelestat-PRM-151-Phase-3-IPF-+-nerandomilast-BAY-1780024-PDE4B-Phase-3-IPF, (ii)-AT2-progenitor-cell-differentiation-as-lung-regeneration-strategy-+-anti-aging-mitochondrial-biogenesis-strategy with-direct-overlap-to-MIC13-MICOS-mitochondrial-liver-disease-+-mitochondrial-biogenesis-lane-from-id:114-yesterday + nicotinamide-riboside-NR-+-NMN-NAD-precursor-strategy, (iii)-VAPA-ALS8-amyotrophic-lateral-sclerosis-progressive-motor-neuron-degeneration-lane with-direct-overlap-to-SOD1-ALS-BBB-crossing-strategy-from-Signal-1. ### 4. Tracker note — Brown Biotech bioinformatics + AI-DD + fibrosis + clinical-translational + drug-delivery + neurodegeneration + cancer-epigenetic + lung-regeneration + mitochondrial-medicine lanes: GSE338996-GSE339010 anchors the FUS-BBB + 4-modality-multiome + microglial-reprogramming + peritumoral-brain-microenvironment + drug-delivery-to-brain lane (BB bioinformatics + AI-DD + clinical-translational core, with direct FUS-BBB-InSightec-ExAblate + CarThera-SonoCloud + Delsona-SonoCare + SonALAsome-pharmacotherapy + Aducanumab-Leqembi-Kisunla-anti-amyloid-BBB-crossing + Lecanemab-Leqembi + prasinezumab-PD-anti-alpha-synuclein + tofersen-Qalsody-SOD1-ALS-ASO + GBM-Stupp-protocol-TMZ-XRT + bevacizumab-Avastin-anti-VEGF-GBM + regorafenib-Stivarga-multi-kinase-GBM + TTFields-Optune + AAV-gene-therapy overlap); GSE346050 anchors the BRD2-MAPKi-PI3K-i + cancer-epigenetic + kinase-inhibitor-combination-therapy + BET-i-sensitivity lane (BB AI-DD + bioinformatics + clinical-translational core, with direct MEK-i-trametinib-Mekinist + cobimetinib-Cotellic + binimetinib-Mektovi + PI3K-i-alpelisib-Piqray + capivasertib-Truqap-AKT-i + BET-i-ABBV-744 + BMS-986158 + PLX51107 + OTX015 + JQ1 + BRD2-degrader-dBET6-dBET1-MZ1-ARV-771 overlap); GSE348519 anchors the VAPA + AT2 + lung-surfactant + ER-MCS + IPF-anti-fibrotic + lung-regeneration lane (BB fibrosis + AI-DD + clinical-translational + longevity core, with direct pirfenidone-Esbriet + nintedanib-Ofev + RGX-104-LXR-APOE + pamrevlumab-FG-3019-anti-CTGF + ziritaxelestat-PRM-151-Pentraxin-2 + nerandomilast-BAY-1780024-PDE4B + senolytic-D-Q-dasatinib-quercetin + navitoclax-ABT-263 + metformin-TAME + SFTPB-SFTPC-ABCA3-surfactant + ABCA3-surfactant-deficiency + neonatal-RDS-surfactant-replacement-therapy + ARDS-COVID-19-lung-recovery overlap). The 3 picks span 3 distinct BB lanes (bioinformatics + AI-DD + fibrosis), all ABSENT from the id:108-id:114 retention window per regex-dedup, all Homo sapiens, with combined pdat-window 2026/10/01-to-2026/10/02 (3-2 days ago range), with a combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=1/5, AI-DD=4/5, longevity=4/5, cost=5/5 — the AI-DD + cost axes dominate (FUS-BBB-clinical-trials-active + BRD2-MAPKi-PI3K-i-combination-strategy + VAPA-AT2-lung-regeneration-strategy all leverage ESTABLISHED clinical assets with low marginal-cost-to-repurpose). --- ## 💼 Next Steps - **[Open GSE338996 in GEO (FUS-BBB Multiome scATAC, n=8, score 9, pdat 2026/10/01)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE338996)** - **[Open GSE338999 in GEO (FUS-BBB Visium, n=4, score 9, pdat 2026/10/01)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE338999)** - **[Open GSE339006 in GEO (FUS-BBB Xenium, n=10, score 9, pdat 2026/10/01)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339006)** - **[Open GSE339010 in GEO (FUS-BBB scRNA-Seq, n=14, score 9, pdat 2026/10/01)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339010)** - **[Open GSE346050 in GEO (BRD2-MAPKi-PI3K/AKT-i sensitivity KO RNA-seq, n=12, score 6, pdat 2026/10/01)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE346050)** - **[Open GSE348519 in GEO (VAPA-AT2 lung surfactant, n=8, score 6, pdat 2026/10/02 = FRESHEST)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE348519)** - **[Read InSightec ExAblate Navigo / CarThera SonoCloud FUS-BBB clinical trial overview](https://clinicaltrials.gov/search?intr=Focused+Ultrasound+BBB)** - **[Read BET inhibitor ABBV-744 + BMS-986158 clinical development](https://clinicaltrials.gov/search?intr=BET+inhibitor)** - **[Read pirfenidone (Esbriet, FDA-approved 2014 IPF) FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022535s010lbl.pdf)** - **[Request FUS-BBB + 4-modality-multiome + microglial-reprogramming brief](https://brownbio.tech/services/biostatx#brief)** - **[Request BRD2-MAPKi-PI3K-i + cancer-epigenetic + combination-therapy-strategy brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request VAPA-AT2 + lung-surfactant + IPF-anti-fibrotic + lung-regeneration brief](https://brownbio.tech/services/fibrosis#brief)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-04 06:14 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-04
PubMed/GEO scan · research-watcher · 06:00 KST